GovChime
Notice ID: ddb5dfb0987149fbb6740e0ccfc7d64bAward NoticeAwarded

65--Pharm Manuf/Distr Div - FSA

Awarded on October 28, 2024. The description is published on SAM.gov: Full description on SAM.gov.

Awarded tounder SPE2D225D0001 (source: SAM.gov award notice)• $15.3M

Overview

Posted
October 28, 2024
Notice type
Award Notice
NAICS
325411: Medicinal and Botanical Manufacturing
Agency
Department of WarDEFENSE LOGISTICS AGENCY

Notice details

Office
DLA TROOP SUPPORT
PSC
65: MEDICAL/DENTAL/VETERINARY EQPT/SUPP
Last updated
Dec 5, 2025
Award date
Oct 28, 2024
Award amount (SAM.gov award notice)
$15.3M

Identifiers

Solicitation number
SPE2D224R0004
Notice ID
ddb5dfb0987149fbb6740e0ccfc7d64b
Award number (PIID)
SPE2D225D0001

Description

No description in the SAM.gov data feed for this notice.

Full description on SAM.gov

Award Overview

Award Number

SPE2D225D0001

Award Amount (SAM.gov award notice)

$15.3M

Award Date

Oct 28, 2024

Awardee

Awardee UEI

GQLDJJ8AQNN5

Awardee CAGE Code

1HT23

Original Solicitation

Notice ID: ddb5dfb0987149fbb6740e0ccfc7d64b

Posted Date: Oct 28, 2024

Original Response Deadline: Not specified

More From This Vendor

Top 5 most recent

5
  • SPE2D326F386H
    GOLDEN STATE MEDICAL SUPPLY, INC.
    Department of DefenseNAICS 325412
    $78.72Signed Aug 14, 2026
  • SPE2D326F375Z
    GOLDEN STATE MEDICAL SUPPLY, INC.
    Department of DefenseNAICS 325412
    $27.3Signed Aug 12, 2026
  • SPE2D326F373Z
    GOLDEN STATE MEDICAL SUPPLY, INC.
    Department of DefenseNAICS 325412
    $535.44Signed Aug 12, 2026
  • SPE2D326F373X
    GOLDEN STATE MEDICAL SUPPLY, INC.
    Department of DefenseNAICS 325412
    $147.36Signed Aug 12, 2026
  • SPE2D326F359Y
    GOLDEN STATE MEDICAL SUPPLY, INC.
    Department of DefenseNAICS 325412
    $85.96Signed Aug 10, 2026

Contacts

Contracting Officer

Primary Contact

LISA QUINN215-737-8787

Documents

No documents available.

Lifecycle

Solicitation:SPE2D224R0004
  1. Awarded

This opportunity has been awarded.

  1. AwardedCurrentOct 28, 2024

    65--Pharm Manuf/Distr Div - FSA

    Notice ddb5dfb0987149fbb6740e0ccfc7d64b on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Amendment 0004 has been issued to extend the solicitation to July 08, 2025.
46%
Solicitation07/08/2025
Solicitation is attached.
46%
Solicitation10/06/2025
Solicitation is attached.
46%
Solicitation09/26/2025
Celecoxib Capsules Solicitation SPE2D2-25-R-0021.
46%
Solicitation09/25/2025
The Defense Logistics Agency is planning to issue a solicitation for a national requirements contract for Ondansetron Orally Disintegrating Tablets (ODT). Procurement details follow. Ondansetron ODT 4 MG Tablet in 30 count bottles. Ondansetron ODT 8 MG Tablet in 10 and 30 count bottles. This will be an unrestricted and fully competitive acquisition. The contract will be a firm-fixed price, requirements type contract with a one-year base and four one-year options. A contract resulting from this solicitation will establish a national supply source, in accordance with FAR 52.216-21 (Requirements), to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service and Bureau of Prisons customers through the DLA and VA prime vendor programs. The annual usage estimates will be provided in the Schedule of Supplies section of the solicitation. This is a commercial item and will be solicited using FAR part 12. All sources may submit a proposal which shall be considered by the agency. A copy of the solicitation will be posted to the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil and Sam.Gov at https://sam.gov. Interested parties should contact Nancy Fernandez at (445) 737-0713, (Nancy.Fernandez@dla.mil) for any questions/comments. Interested parties are further advised to set up automated notifications of pre-solicitation or solicitation changes through this website. The current projected solicitation date is September of 2025. DLA reserves the right to issue the solicitation before or after the projected solicitation date. *The Ondansetron HCL Tablets will be solicited in a separate acquisition.
46%
Pre-SolicitationOpen

Additional Details

Solicitation Number

SPE2D224R0004

Archive Date

Nov 12, 2024